No Data
No Data
Buy Rating Affirmed for BioAtla on Strong Clinical Data and Robust Financials
LIDR, HOOK and BCAB Among Mid-day Movers
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB),today announced expanded data at an upcoming presentation entitled, "Phase 1 study of evalstotug (BA3071), an anti-CTLA-4 Conditionally Active Biologic, in combination with nivolumab in advanced solid tumors", demonstrating confirmed responses with a potentially differentiated tolerability profile with the Company's novel, conditionally active anti-CTLA-4 agent, evalstotug, in combination with anti-PD-1 therapy.
BioAtla Is Maintained at Market Outperform by JMP Securities
BioAtla Is Maintained at Market Outperform by JMP Securities
BioAtla Price Target Cut to $5.00/Share From $12.00 by JMP Securities
BioAtla Price Target Cut to $5.00/Share From $12.00 by JMP Securities
Institutional Owners May Consider Drastic Measures as BioAtla, Inc.'s (NASDAQ:BCAB) Recent US$35m Drop Adds to Long-term Losses
No Data